APO Research
Talk to an analyst

APO RESEARCH · REPORT

Poliovirus Vaccine Inactivated

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Poliovirus Vaccine Inactivated Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchPoliovirus Vaccine Inactivated Industry Research Report 2026113 pages · $2,950 USDIndustry Growth & TrendsGlobal Poliovirus Vaccine Inactivated Industry Growth and Trends Forecast to 203279 pages · $3,450 USDMarket StructureGlobal Poliovirus Vaccine Inactivated Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032172 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Poliovirus Vaccine Inactivated Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Poliovirus Vaccine Inactivated Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Poliovirus Vaccine Inactivated market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Poliovirus Vaccine Inactivated is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Poliovirus Vaccine Inactivated is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Poliovirus Vaccine Inactivated is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Poliovirus Vaccine Inactivated market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Poliovirus Vaccine Inactivated market include IMBCA, Serum Institute (Bilthoven Biologicals), GSK and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Poliovirus Vaccine Inactivated market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Poliovirus Vaccine Inactivated and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Poliovirus Vaccine Inactivated sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Poliovirus Vaccine Inactivated market size, projected growth trends, production technologies, key applications, and end-use industries.

Poliovirus Vaccine Inactivated Segment by Company

IMBCA

Serum Institute (Bilthoven Biologicals)

GSK

Sanofi

Poliovirus Vaccine Inactivated Segment by Type

Human Diploid Cell

Monkey Kidney Cell

Poliovirus Vaccine Inactivated Segment by Application

Public

Private

Poliovirus Vaccine Inactivated Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Poliovirus Vaccine Inactivated status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Poliovirus Vaccine Inactivated market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Poliovirus Vaccine Inactivated significant trends, drivers, influence factors in global and regions.

6. To analyze Poliovirus Vaccine Inactivated competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Poliovirus Vaccine Inactivated market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Poliovirus Vaccine Inactivated and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Poliovirus Vaccine Inactivated.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Poliovirus Vaccine Inactivated market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Poliovirus Vaccine Inactivated industry.

Chapter 3: Detailed analysis of Poliovirus Vaccine Inactivated manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Poliovirus Vaccine Inactivated in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Poliovirus Vaccine Inactivated in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Poliovirus Vaccine Inactivated Industry Trends Table 2. Poliovirus Vaccine Inactivated Industry Drivers Table 3. Poliovirus Vaccine Inactivated Industry Opportunities and Challenges Table 4. Poliovirus Vaccine Inactivated Industry Restraints Table 5. Global Poliovirus Vaccine Inactivated Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Poliovirus Vaccine Inactivated Revenue Share by Company (2021-2026) Table 7. Global Poliovirus Vaccine Inactivated Sales Volume by Company (k units) & (2021-2026) Table 8. Global Poliovirus Vaccine Inactivated Sales Volume Share by Company (2021-2026) Table 9. Global Poliovirus Vaccine Inactivated Average Price (US$/unit) of Company (2021-2026) Table 10. Global Poliovirus Vaccine Inactivated Company Ranking, (2024-2026) & (USD Million) Table 11. Global Poliovirus Vaccine Inactivated Key Company Manufacturing Base & Headquarters Table 12. Global Poliovirus Vaccine Inactivated Company, Product Type & Application Table 13. Global Poliovirus Vaccine Inactivated Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Poliovirus Vaccine Inactivated by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Human Diploid Cell Table 18. Significant Companies of Monkey Kidney Cell Table 19. Global Poliovirus Vaccine Inactivated Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Poliovirus Vaccine Inactivated Sales Volume by Type (2021-2026) & (k units) Table 21. Global Poliovirus Vaccine Inactivated Sales Volume by Type (2027-2032) & (k units) Table 22. Global Poliovirus Vaccine Inactivated Sales Volume Share by Type (2021-2026) Table 23. Global Poliovirus Vaccine Inactivated Sales Volume Share by Type (2027-2032) Table 24. Global Poliovirus Vaccine Inactivated Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Poliovirus Vaccine Inactivated Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Poliovirus Vaccine Inactivated Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Poliovirus Vaccine Inactivated Sales Value Share by Type (2021-2026) Table 28. Global Poliovirus Vaccine Inactivated Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Public Table 30. Significant Companies of Private Table 31. Global Poliovirus Vaccine Inactivated Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Poliovirus Vaccine Inactivated Sales Volume by Application (2021-2026) & (k units) Table 33. Global Poliovirus Vaccine Inactivated Sales Volume by Application (2027-2032) & (k units) Table 34. Global Poliovirus Vaccine Inactivated Sales Volume Share by Application (2021-2026) Table 35. Global Poliovirus Vaccine Inactivated Sales Volume Share by Application (2027-2032) Table 36. Global Poliovirus Vaccine Inactivated Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Poliovirus Vaccine Inactivated Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Poliovirus Vaccine Inactivated Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Poliovirus Vaccine Inactivated Sales Value Share by Application (2021-2026) Table 40. Global Poliovirus Vaccine Inactivated Sales Value Share by Application (2027-2032) Table 41. Global Poliovirus Vaccine Inactivated Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Poliovirus Vaccine Inactivated Sales by Region (2021-2026) & (k units) Table 43. Global Poliovirus Vaccine Inactivated Sales Market Share by Region (2021-2026) Table 44. Global Poliovirus Vaccine Inactivated Sales by Region (2027-2032) & (k units) Table 45. Global Poliovirus Vaccine Inactivated Sales Market Share by Region (2027-2032) Table 46. Global Poliovirus Vaccine Inactivated Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Poliovirus Vaccine Inactivated Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Poliovirus Vaccine Inactivated Sales Value Share by Region (2021-2026) Table 49. Global Poliovirus Vaccine Inactivated Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Poliovirus Vaccine Inactivated Sales Value Share by Region (2027-2032) Table 51. Global Poliovirus Vaccine Inactivated Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Poliovirus Vaccine Inactivated Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Poliovirus Vaccine Inactivated Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Poliovirus Vaccine Inactivated Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Poliovirus Vaccine Inactivated Sales by Country (2021-2026) & (k units) Table 56. Global Poliovirus Vaccine Inactivated Sales Market Share by Country (2021-2026) Table 57. Global Poliovirus Vaccine Inactivated Sales by Country (2027-2032) & (k units) Table 58. Global Poliovirus Vaccine Inactivated Sales Market Share by Country (2027-2032) Table 59. Global Poliovirus Vaccine Inactivated Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Poliovirus Vaccine Inactivated Sales Value Market Share by Country (2021-2026) Table 61. Global Poliovirus Vaccine Inactivated Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Poliovirus Vaccine Inactivated Sales Value Market Share by Country (2027-2032) Table 63. IMBCA Company Information Table 64. IMBCA Business Overview Table 65. IMBCA Poliovirus Vaccine Inactivated Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. IMBCA Poliovirus Vaccine Inactivated Product Portfolio Table 67. IMBCA Recent Development Table 68. Serum Institute (Bilthoven Biologicals) Company Information Table 69. Serum Institute (Bilthoven Biologicals) Business Overview Table 70. Serum Institute (Bilthoven Biologicals) Poliovirus Vaccine Inactivated Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Serum Institute (Bilthoven Biologicals) Poliovirus Vaccine Inactivated Product Portfolio Table 72. Serum Institute (Bilthoven Biologicals) Recent Development Table 73. GSK Company Information Table 74. GSK Business Overview Table 75. GSK Poliovirus Vaccine Inactivated Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. GSK Poliovirus Vaccine Inactivated Product Portfolio Table 77. GSK Recent Development Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi Poliovirus Vaccine Inactivated Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Sanofi Poliovirus Vaccine Inactivated Product Portfolio Table 82. Sanofi Recent Development Table 83. Key Raw Materials Table 84. Raw Materials Key Suppliers Table 85. Poliovirus Vaccine Inactivated Distributors List Table 86. Poliovirus Vaccine Inactivated Customers List Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Poliovirus Vaccine Inactivated Product Image Figure 2. Global Poliovirus Vaccine Inactivated Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Poliovirus Vaccine Inactivated Sales Value (2021-2032) & (US$ Million) Figure 4. Global Poliovirus Vaccine Inactivated Sales (2021-2032) & (k units) Figure 5. Global Poliovirus Vaccine Inactivated Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Poliovirus Vaccine Inactivated Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Human Diploid Cell Image Figure 10. Monkey Kidney Cell Image Figure 11. Global Poliovirus Vaccine Inactivated Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Poliovirus Vaccine Inactivated Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Poliovirus Vaccine Inactivated Sales Volume Share by Type (2021-2032) Figure 14. Global Poliovirus Vaccine Inactivated Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Poliovirus Vaccine Inactivated Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Poliovirus Vaccine Inactivated Sales Value Share by Type (2021-2032) Figure 17. Public Image Figure 18. Private Image Figure 19. Global Poliovirus Vaccine Inactivated Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Poliovirus Vaccine Inactivated Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Poliovirus Vaccine Inactivated Sales Volume Share by Application (2021-2032) Figure 22. Global Poliovirus Vaccine Inactivated Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Poliovirus Vaccine Inactivated Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Poliovirus Vaccine Inactivated Sales Value Share by Application (2021-2032) Figure 25. Global Poliovirus Vaccine Inactivated Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Poliovirus Vaccine Inactivated Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Poliovirus Vaccine Inactivated Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Poliovirus Vaccine Inactivated Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Poliovirus Vaccine Inactivated Sales Value (2021-2032) & (US$ Million) Figure 30. North America Poliovirus Vaccine Inactivated Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Poliovirus Vaccine Inactivated Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Poliovirus Vaccine Inactivated Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Poliovirus Vaccine Inactivated Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Poliovirus Vaccine Inactivated Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Poliovirus Vaccine Inactivated Sales Value (2021-2032) & (US$ Million) Figure 36. South America Poliovirus Vaccine Inactivated Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Poliovirus Vaccine Inactivated Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Poliovirus Vaccine Inactivated Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Poliovirus Vaccine Inactivated Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Poliovirus Vaccine Inactivated Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Human Diploid Cell
  • Monkey Kidney Cell
Applications
  • Public
  • Private
Companies covered
  • IMBCA
  • Serum Institute (Bilthoven Biologicals)
  • GSK
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Poliovirus Vaccine Inactivated Sales Value (2021-2032)
  4. 1.2.2 Global Poliovirus Vaccine Inactivated Sales Volume (2021-2032)
  5. 1.2.3 Global Poliovirus Vaccine Inactivated Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Poliovirus Vaccine Inactivated Market Dynamics
  1. 2.1 Poliovirus Vaccine Inactivated Industry Trends
  2. 2.2 Poliovirus Vaccine Inactivated Industry Drivers
  3. 2.3 Poliovirus Vaccine Inactivated Industry Opportunities and Challenges
  4. 2.4 Poliovirus Vaccine Inactivated Industry Restraints
3 Poliovirus Vaccine Inactivated Market by Company
  1. 3.1 Global Poliovirus Vaccine Inactivated Company Revenue Ranking in 2025
  2. 3.2 Global Poliovirus Vaccine Inactivated Revenue by Company (2021-2026)
  3. 3.3 Global Poliovirus Vaccine Inactivated Sales Volume by Company (2021-2026)
  4. 3.4 Global Poliovirus Vaccine Inactivated Average Price by Company (2021-2026)
  5. 3.5 Global Poliovirus Vaccine Inactivated Company Ranking (2024-2026)
  6. 3.6 Global Poliovirus Vaccine Inactivated Company Manufacturing Base and Headquarters
  7. 3.7 Global Poliovirus Vaccine Inactivated Company Product Type and Application
  8. 3.8 Global Poliovirus Vaccine Inactivated Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Poliovirus Vaccine Inactivated Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Poliovirus Vaccine Inactivated Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Poliovirus Vaccine Inactivated Market by Type
  1. 4.1 Poliovirus Vaccine Inactivated Type Introduction
  2. 4.1.1 Human Diploid Cell
  3. 4.1.2 Monkey Kidney Cell
  4. 4.2 Global Poliovirus Vaccine Inactivated Sales Volume by Type
  5. 4.2.1 Global Poliovirus Vaccine Inactivated Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Poliovirus Vaccine Inactivated Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Poliovirus Vaccine Inactivated Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Poliovirus Vaccine Inactivated Sales Value by Type
  9. 4.3.1 Global Poliovirus Vaccine Inactivated Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Poliovirus Vaccine Inactivated Sales Value by Type (2021-2032)
  11. 4.3.3 Global Poliovirus Vaccine Inactivated Sales Value Share by Type (2021-2032)
5 Poliovirus Vaccine Inactivated Market by Application
  1. 5.1 Poliovirus Vaccine Inactivated Application Introduction
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Poliovirus Vaccine Inactivated Sales Volume by Application
  5. 5.2.1 Global Poliovirus Vaccine Inactivated Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Poliovirus Vaccine Inactivated Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Poliovirus Vaccine Inactivated Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Poliovirus Vaccine Inactivated Sales Value by Application
  9. 5.3.1 Global Poliovirus Vaccine Inactivated Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Poliovirus Vaccine Inactivated Sales Value by Application (2021-2032)
  11. 5.3.3 Global Poliovirus Vaccine Inactivated Sales Value Share by Application (2021-2032)
6 Poliovirus Vaccine Inactivated Regional Sales and Value Analysis
  1. 6.1 Global Poliovirus Vaccine Inactivated Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Poliovirus Vaccine Inactivated Sales by Region (2021-2032)
  3. 6.2.1 Global Poliovirus Vaccine Inactivated Sales by Region: 2021-2026
  4. 6.2.2 Global Poliovirus Vaccine Inactivated Sales by Region (2027-2032)
  5. 6.3 Global Poliovirus Vaccine Inactivated Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Poliovirus Vaccine Inactivated Sales Value by Region (2021-2032)
  7. 6.4.1 Global Poliovirus Vaccine Inactivated Sales Value by Region: 2021-2026
  8. 6.4.2 Global Poliovirus Vaccine Inactivated Sales Value by Region (2027-2032)
  9. 6.5 Global Poliovirus Vaccine Inactivated Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Poliovirus Vaccine Inactivated Sales Value (2021-2032)
  12. 6.6.2 North America Poliovirus Vaccine Inactivated Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Poliovirus Vaccine Inactivated Sales Value (2021-2032)
  15. 6.7.2 Europe Poliovirus Vaccine Inactivated Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Poliovirus Vaccine Inactivated Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Poliovirus Vaccine Inactivated Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Poliovirus Vaccine Inactivated Sales Value (2021-2032)
  21. 6.9.2 South America Poliovirus Vaccine Inactivated Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Poliovirus Vaccine Inactivated Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Poliovirus Vaccine Inactivated Sales Value Share by Country, 2025 VS 2032
7 Poliovirus Vaccine Inactivated Country-level Sales and Value Analysis
  1. 7.1 Global Poliovirus Vaccine Inactivated Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Poliovirus Vaccine Inactivated Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Poliovirus Vaccine Inactivated Sales by Country (2021-2032)
  4. 7.3.1 Global Poliovirus Vaccine Inactivated Sales by Country (2021-2026)
  5. 7.3.2 Global Poliovirus Vaccine Inactivated Sales by Country (2027-2032)
  6. 7.4 Global Poliovirus Vaccine Inactivated Sales Value by Country (2021-2032)
  7. 7.4.1 Global Poliovirus Vaccine Inactivated Sales Value by Country (2021-2026)
  8. 7.4.2 Global Poliovirus Vaccine Inactivated Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Poliovirus Vaccine Inactivated Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Poliovirus Vaccine Inactivated Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Poliovirus Vaccine Inactivated Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 IMBCA
  2. 8.1.1 IMBCA Company Information
  3. 8.1.2 IMBCA Business Overview
  4. 8.1.3 IMBCA Poliovirus Vaccine Inactivated Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 IMBCA Poliovirus Vaccine Inactivated Product Portfolio
  6. 8.1.5 IMBCA Recent Developments
  7. 8.2 Serum Institute (Bilthoven Biologicals)
  8. 8.2.1 Serum Institute (Bilthoven Biologicals) Company Information
  9. 8.2.2 Serum Institute (Bilthoven Biologicals) Business Overview
  10. 8.2.3 Serum Institute (Bilthoven Biologicals) Poliovirus Vaccine Inactivated Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Serum Institute (Bilthoven Biologicals) Poliovirus Vaccine Inactivated Product Portfolio
  12. 8.2.5 Serum Institute (Bilthoven Biologicals) Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Poliovirus Vaccine Inactivated Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GSK Poliovirus Vaccine Inactivated Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Poliovirus Vaccine Inactivated Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Poliovirus Vaccine Inactivated Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Poliovirus Vaccine Inactivated Value Chain Analysis
  2. 9.1.1 Poliovirus Vaccine Inactivated Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Poliovirus Vaccine Inactivated Sales Mode & Process
  6. 9.2 Poliovirus Vaccine Inactivated Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Poliovirus Vaccine Inactivated Distributors
  9. 9.2.3 Poliovirus Vaccine Inactivated Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst